Skip to main content
. 2015 Jun 26;10(6):e0130872. doi: 10.1371/journal.pone.0130872

Fig 2. Kaplan-Meier Analysis of Overall Survival and Progression-free Survival According to IDH1 Status and Adjuvant Treatment.

Fig 2

A comparison of (A) overall survival (OS) and (B) progression-free survival (PFS) between patients with IDH1 wild-type (IDH1 WT) grade II gliomas who received radiotherapy (RT) or radiotherapy plus chemotherapy (RT+CT). A comparison of (C) OS and (D) PFS between patients with IDH1-mutated (IDH1 MT) grade II gliomas who received RT or RT+CT. For the IDH1 WT group, PFS and OS were longer in patients who underwent RT compared with those who underwent RT+CT (p = 0.002). For the IDH1 MT group, PFS and OS were not significantly different between patients who underwent RT or RT+CT (p = 0.194).